The female fertility and pregnancy rapid test market size has grown strongly in recent years. It will grow from $1.48 billion in 2025 to $1.58 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising awareness of female reproductive health, increasing use of ovulation predictor kits, growing retail availability of rapid tests, expansion of hospital-based diagnostic testing, increasing incidence of infertility diagnoses.
The female fertility and pregnancy rapid test market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing demand for early pregnancy detection, rising adoption of digital health monitoring solutions, growing focus on personalized fertility management, expansion of telehealth-supported diagnostics, increasing penetration of e-commerce healthcare products. Major trends in the forecast period include increasing adoption of at-home rapid testing kits, rising demand for digital and app-connected test devices, growing use of combo fertility and pregnancy tests, expansion of online distribution channels, enhanced focus on user-friendly and accurate test designs.
The rising prevalence of gynecological disorders is anticipated to drive growth in the female fertility and pregnancy rapid test market. Gynecological disorders affect the female reproductive system and can include various conditions impacting the uterus, ovaries, vagina, and other related organs. Diagnosing fertility-related issues through tests can address infertility problems, reducing the impact of gynecological disorders. According to a July 2022 report by the National Library of Medicine, prevalent gynecological disorders encompass ailments such as uterine fibroids, spontaneous abortion, ovarian dysfunction, endometriosis, polycystic ovary syndrome, and dysmenorrhea. Hence, the market for female fertility and pregnancy rapid tests is experiencing growth due to the increasing occurrence of such disorders.
Major companies operating in the female fertility and pregnancy rapid test market are increasingly prioritizing the development of innovative solutions, such as saliva-based home pregnancy tests, to address the growing demand for non-invasive and user-friendly diagnostic options. A saliva-based pregnancy test is a lateral-flow, point-of-care assay that identifies pregnancy biomarkers in oral fluid instead of urine. For instance, in May 2024, Abingdon Health plc, a United Kingdom-based lateral flow contract development and manufacturing organization, launched the world’s first Boots-branded saliva pregnancy self-test, which is available both in Boots retail stores and online, bringing saliva-based pregnancy testing into the mainstream consumer market. The product consists of a saliva collection interface and a proprietary lateral-flow immunoassay developed in collaboration with Salignostics and Crest Medical, designed to bind to and indicate the presence of pregnancy biomarkers in oral fluid. It operates as a rapid, single-use self-test that delivers results within minutes and is packaged for over-the-counter sale. By eliminating urine collection from the testing process, the test improves comfort and hygiene, supports consumer adoption through a familiar stick or cassette format, and is intended for routine home screening and early pregnancy confirmation, further strengthened by the extensive retail reach and consumer trust associated with Boots.
In July 2023, Quest Diagnostics Incorporated, a United States-based healthcare diagnostics company, entered into a partnership with Proov Inc. Through this collaboration, Quest Diagnostics Incorporated sought to expand its consumer-initiated testing portfolio and improve access to at-home fertility testing by offering Proov’s United States Food and Drug Administration-cleared Proov Confirm PdG home test via questhealth.com. Proov Inc. is a United States-based health technology company that focuses on at-home pregnanediol glucuronide urine testing and complementary digital tools designed to help women confirm successful ovulation.
Major companies operating in the female fertility and pregnancy rapid test market are Abbott Laboratories, Atlas Medical GmbH, bioMérieux SA, Church & Dwight Co. Inc., Quidel Corporation, Egens Group, Eurofins Scientific SE, Everlywell Inc., Genea Pty Limited, Geratherm Medical AG, SA Scientific Ltd., Artron Laboratories Inc., PRIMA Lab SA, The Procter & Gamble Company, Alere Inc., Prestige Brands Holdings Inc., SPD Swiss Precision Diagnostics GmbH, Fairhaven Health LLC, Fertility Focus Limited, HiLin Life Products Inc., Inverness Medical Innovations Inc., UEBE Medical GmbH, Wondfo Biotech Co. Ltd.
North America was the largest region in the female fertility and pregnancy rapid test market in 2025. The regions covered in the female fertility and pregnancy rapid test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the female fertility and pregnancy rapid test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the female fertility and pregnancy rapid test market by increasing costs of imported diagnostic reagents, test strips, digital readers, and electronic components used in advanced testing devices. Manufacturers and distributors in North America and Europe are most affected due to dependence on imported raw materials, while Asia-Pacific faces pricing pressure on export-oriented production. These tariffs are raising retail prices and impacting affordability for consumers. However, they are also encouraging localized manufacturing, regional sourcing of consumables, and investment in cost-efficient test kit production.
The female fertility and pregnancy rapid test market research report is one of a series of new reports that provides female fertility and pregnancy rapid test market statistics, including female fertility and pregnancy rapid test industry global market size, regional shares, competitors with a female fertility and pregnancy rapid test market share, detailed female fertility and pregnancy rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the female fertility and pregnancy rapid test industry. This female fertility and pregnancy rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The female fertility and pregnancy rapid tests involve methods for testing fertility and pregnancy in women, utilizing drugstore-bought urine tests and blood tests conducted at a doctor's office. These rapid test kits offer a straightforward and user-friendly solution for fertility testing, aiming to detect ovulation and diagnose infertility in females.
The primary products in the female fertility and pregnancy rapid tests category include fertility rapid test kits and pregnancy rapid test kits. Fertility rapid tests are in vitro diagnostic tools designed for the qualitative identification and assessment of pregnancy, fertility cycles, ovulation, and sperm counts within minutes. These devices come in various forms, including digital devices and line-indicator devices, and can be utilized for tests such as FSH urine test, LH urine test, HCG blood testing, and HCG urine testing. These kits are available through different distribution channels, including hospitals, retail outlets, and online platforms.
The female fertility and pregnancy rapid test market consists of sales of urine and blood test kits used to detect female pregnancy and fertility. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The female fertility and pregnancy rapid test market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing demand for early pregnancy detection, rising adoption of digital health monitoring solutions, growing focus on personalized fertility management, expansion of telehealth-supported diagnostics, increasing penetration of e-commerce healthcare products. Major trends in the forecast period include increasing adoption of at-home rapid testing kits, rising demand for digital and app-connected test devices, growing use of combo fertility and pregnancy tests, expansion of online distribution channels, enhanced focus on user-friendly and accurate test designs.
The rising prevalence of gynecological disorders is anticipated to drive growth in the female fertility and pregnancy rapid test market. Gynecological disorders affect the female reproductive system and can include various conditions impacting the uterus, ovaries, vagina, and other related organs. Diagnosing fertility-related issues through tests can address infertility problems, reducing the impact of gynecological disorders. According to a July 2022 report by the National Library of Medicine, prevalent gynecological disorders encompass ailments such as uterine fibroids, spontaneous abortion, ovarian dysfunction, endometriosis, polycystic ovary syndrome, and dysmenorrhea. Hence, the market for female fertility and pregnancy rapid tests is experiencing growth due to the increasing occurrence of such disorders.
Major companies operating in the female fertility and pregnancy rapid test market are increasingly prioritizing the development of innovative solutions, such as saliva-based home pregnancy tests, to address the growing demand for non-invasive and user-friendly diagnostic options. A saliva-based pregnancy test is a lateral-flow, point-of-care assay that identifies pregnancy biomarkers in oral fluid instead of urine. For instance, in May 2024, Abingdon Health plc, a United Kingdom-based lateral flow contract development and manufacturing organization, launched the world’s first Boots-branded saliva pregnancy self-test, which is available both in Boots retail stores and online, bringing saliva-based pregnancy testing into the mainstream consumer market. The product consists of a saliva collection interface and a proprietary lateral-flow immunoassay developed in collaboration with Salignostics and Crest Medical, designed to bind to and indicate the presence of pregnancy biomarkers in oral fluid. It operates as a rapid, single-use self-test that delivers results within minutes and is packaged for over-the-counter sale. By eliminating urine collection from the testing process, the test improves comfort and hygiene, supports consumer adoption through a familiar stick or cassette format, and is intended for routine home screening and early pregnancy confirmation, further strengthened by the extensive retail reach and consumer trust associated with Boots.
In July 2023, Quest Diagnostics Incorporated, a United States-based healthcare diagnostics company, entered into a partnership with Proov Inc. Through this collaboration, Quest Diagnostics Incorporated sought to expand its consumer-initiated testing portfolio and improve access to at-home fertility testing by offering Proov’s United States Food and Drug Administration-cleared Proov Confirm PdG home test via questhealth.com. Proov Inc. is a United States-based health technology company that focuses on at-home pregnanediol glucuronide urine testing and complementary digital tools designed to help women confirm successful ovulation.
Major companies operating in the female fertility and pregnancy rapid test market are Abbott Laboratories, Atlas Medical GmbH, bioMérieux SA, Church & Dwight Co. Inc., Quidel Corporation, Egens Group, Eurofins Scientific SE, Everlywell Inc., Genea Pty Limited, Geratherm Medical AG, SA Scientific Ltd., Artron Laboratories Inc., PRIMA Lab SA, The Procter & Gamble Company, Alere Inc., Prestige Brands Holdings Inc., SPD Swiss Precision Diagnostics GmbH, Fairhaven Health LLC, Fertility Focus Limited, HiLin Life Products Inc., Inverness Medical Innovations Inc., UEBE Medical GmbH, Wondfo Biotech Co. Ltd.
North America was the largest region in the female fertility and pregnancy rapid test market in 2025. The regions covered in the female fertility and pregnancy rapid test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the female fertility and pregnancy rapid test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the female fertility and pregnancy rapid test market by increasing costs of imported diagnostic reagents, test strips, digital readers, and electronic components used in advanced testing devices. Manufacturers and distributors in North America and Europe are most affected due to dependence on imported raw materials, while Asia-Pacific faces pricing pressure on export-oriented production. These tariffs are raising retail prices and impacting affordability for consumers. However, they are also encouraging localized manufacturing, regional sourcing of consumables, and investment in cost-efficient test kit production.
The female fertility and pregnancy rapid test market research report is one of a series of new reports that provides female fertility and pregnancy rapid test market statistics, including female fertility and pregnancy rapid test industry global market size, regional shares, competitors with a female fertility and pregnancy rapid test market share, detailed female fertility and pregnancy rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the female fertility and pregnancy rapid test industry. This female fertility and pregnancy rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The female fertility and pregnancy rapid tests involve methods for testing fertility and pregnancy in women, utilizing drugstore-bought urine tests and blood tests conducted at a doctor's office. These rapid test kits offer a straightforward and user-friendly solution for fertility testing, aiming to detect ovulation and diagnose infertility in females.
The primary products in the female fertility and pregnancy rapid tests category include fertility rapid test kits and pregnancy rapid test kits. Fertility rapid tests are in vitro diagnostic tools designed for the qualitative identification and assessment of pregnancy, fertility cycles, ovulation, and sperm counts within minutes. These devices come in various forms, including digital devices and line-indicator devices, and can be utilized for tests such as FSH urine test, LH urine test, HCG blood testing, and HCG urine testing. These kits are available through different distribution channels, including hospitals, retail outlets, and online platforms.
The female fertility and pregnancy rapid test market consists of sales of urine and blood test kits used to detect female pregnancy and fertility. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Female Fertility and Pregnancy Rapid Test Market Characteristics
3. Female Fertility and Pregnancy Rapid Test Market Supply Chain Analysis
4. Global Female Fertility and Pregnancy Rapid Test Market Trends and Strategies
5. Female Fertility and Pregnancy Rapid Test Market Analysis of End Use Industries
7. Global Female Fertility and Pregnancy Rapid Test Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Female Fertility and Pregnancy Rapid Test Total Addressable Market (TAM) Analysis for the Market
9. Female Fertility and Pregnancy Rapid Test Market Segmentation
10. Female Fertility and Pregnancy Rapid Test Market Regional and Country Analysis
11. Asia-Pacific Female Fertility and Pregnancy Rapid Test Market
12. China Female Fertility and Pregnancy Rapid Test Market
13. India Female Fertility and Pregnancy Rapid Test Market
14. Japan Female Fertility and Pregnancy Rapid Test Market
15. Australia Female Fertility and Pregnancy Rapid Test Market
16. Indonesia Female Fertility and Pregnancy Rapid Test Market
17. South Korea Female Fertility and Pregnancy Rapid Test Market
18. Taiwan Female Fertility and Pregnancy Rapid Test Market
19. South East Asia Female Fertility and Pregnancy Rapid Test Market
20. Western Europe Female Fertility and Pregnancy Rapid Test Market
21. UK Female Fertility and Pregnancy Rapid Test Market
22. Germany Female Fertility and Pregnancy Rapid Test Market
23. France Female Fertility and Pregnancy Rapid Test Market
24. Italy Female Fertility and Pregnancy Rapid Test Market
25. Spain Female Fertility and Pregnancy Rapid Test Market
26. Eastern Europe Female Fertility and Pregnancy Rapid Test Market
27. Russia Female Fertility and Pregnancy Rapid Test Market
28. North America Female Fertility and Pregnancy Rapid Test Market
29. USA Female Fertility and Pregnancy Rapid Test Market
30. Canada Female Fertility and Pregnancy Rapid Test Market
31. South America Female Fertility and Pregnancy Rapid Test Market
32. Brazil Female Fertility and Pregnancy Rapid Test Market
33. Middle East Female Fertility and Pregnancy Rapid Test Market
34. Africa Female Fertility and Pregnancy Rapid Test Market
36. Female Fertility and Pregnancy Rapid Test Market Competitive Landscape and Company Profiles
37. Female Fertility and Pregnancy Rapid Test Market Other Major and Innovative Companies
40. Female Fertility and Pregnancy Rapid Test Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Female Fertility And Pregnancy Rapid Test Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses female fertility and pregnancy rapid test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for female fertility and pregnancy rapid test? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The female fertility and pregnancy rapid test market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Fertility Rapid Test Kits; Pregnancy Rapid Test Kits2) By Device Type: Digital Devices; Line-indicator Devices
3) By Test Type: FSH Urine Test; LH Urine Test; hCG Blood Test; hCG Urine Test
4) By Distribution Channel: Hospital Channel; Retail Channel; Online Channel
Subsegments:
1) By Fertility Rapid Test Kits: Ovulation Predictor Kits; Luteinizing Hormone (LH) Test Kits; Follicle-Stimulating Hormone (FSH) Test Kits2) By Pregnancy Rapid Test Kits: Urine-Based Pregnancy Tests; Blood-Based Pregnancy Tests; Combo Fertility And Pregnancy Tests
Companies Mentioned: Abbott Laboratories; Atlas Medical GmbH; bioMérieux SA; Church & Dwight Co. Inc.; Quidel Corporation; Egens Group; Eurofins Scientific SE; Everlywell Inc.; Genea Pty Limited; Geratherm Medical AG; SA Scientific Ltd.; Artron Laboratories Inc.; PRIMA Lab SA; The Procter & Gamble Company; Alere Inc.; Prestige Brands Holdings Inc.; SPD Swiss Precision Diagnostics GmbH; Fairhaven Health LLC; Fertility Focus Limited; HiLin Life Products Inc.; Inverness Medical Innovations Inc.; UEBE Medical GmbH; Wondfo Biotech Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Female Fertility and Pregnancy Rapid Test market report include:- Abbott Laboratories
- Atlas Medical GmbH
- bioMérieux SA
- Church & Dwight Co. Inc.
- Quidel Corporation
- Egens Group
- Eurofins Scientific SE
- Everlywell Inc.
- Genea Pty Limited
- Geratherm Medical AG
- SA Scientific Ltd.
- Artron Laboratories Inc.
- PRIMA Lab SA
- The Procter & Gamble Company
- Alere Inc.
- Prestige Brands Holdings Inc.
- SPD Swiss Precision Diagnostics GmbH
- Fairhaven Health LLC
- Fertility Focus Limited
- HiLin Life Products Inc.
- Inverness Medical Innovations Inc.
- UEBE Medical GmbH
- Wondfo Biotech Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.58 Billion |
| Forecasted Market Value ( USD | $ 2.05 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
